Nordic biopharma innovation outpaces commercialisation as regional biotechs struggle to raise the capital needed to upscale.
The deal reflects a growing interest from big pharma in the compounds that bridge the gap between small molecules and biologics.
Dualitas is set to receive $36.5m upfront and could become eligible for milestone payments.
The deal grants Ona Therapeutics rights to develop an ADC targeting a single undisclosed target.
The partnership aims to assist GenomeFrontier’s clinical activities for GF-CART01 in the US.
The approval of pitolisant in Japan is based on domestic Phase III studies and international clinical research evidence.
